Proteasome Inhibitor MG132-induced Apoptosis Via ER Stress-mediated Apoptotic Pathway and Its Potentiation by Protein Tyrosine Kinase P56lck in Human Jurkat T Cells
Overview
Pharmacology
Affiliations
Exposure of human Jurkat T cells to MG132 caused apoptosis along with upregulation of Grp78/BiP and CHOP/GADD153, activation of JNK and p38MAPK, activation of Bak, mitochondrial membrane potential (Δψm) loss, cytochrome c release, activation of caspase-12, -9, -3, -7, and -8, cleavage of Bid and PARP, and DNA fragmentation. However, these MG132-induced apoptotic events, with the exceptions of upregulation of Grp78/BiP and CHOP/GADD153 and activation of JNK and p38MAPK, were abrogated by overexpression of Bcl-xL. Pretreatment with the pan-caspase inhibitor z-VAD-fmk prevented MG132-induced apoptotic caspase cascade, but allowed upregulation of Grp78/BiP and CHOP/GADD153 levels, activation of JNK and p38MAPK, Δψm loss, and cleavage of procaspase-9 (47kDa) to active form (35kDa). Further analysis using selective caspase inhibitors revealed that caspase-12 activation was required for activation of caspase-9 and -3 to the sufficient level for subsequent activation of caspase-7 and -8. MG132-induced cytotoxicity, apoptotic sub-G(1) peak, Bak activation, and Δψm loss were markedly reduced by p38MAPK inhibitor, but not by JNK inhibitor. MG132-induced apoptotic changes, including upregulation of Grp78/BiP and CHOP/GADD153 levels, activation of caspase-12, p38MAPK and Bak, and mitochondria-dependent activation of caspase cascade were more significant in p56(lck)-stable transfectant JCaM1.6/lck than in p56(lck)-deficient JCaM1.6/vector. The cytotoxicity of MG132 toward p56(lck)-positive Jurkat T cell clone was not affected by the Src-like kinase inhibitor PP2. These results demonstrated that MG132-induced apoptosis was caused by ER stress and subsequent activation of mitochondria-dependent caspase cascade, and that the presence of p56(lck) enhances MG132-induced apoptosis by augmenting ER stress-mediated apoptotic events in Jurkat T cells.
Pang L, Huang Y, He Y, Jiang D, Li R Nat Commun. 2025; 16(1):2039.
PMID: 40016204 PMC: 11868639. DOI: 10.1038/s41467-025-57306-7.
Proteasome inhibitor MG132 modulates signal transduction pathways in ELT3 uterine leiomyoma cells.
Joung H, Yang S, Lee S, Liu H Exp Ther Med. 2025; 29(4):71.
PMID: 39991715 PMC: 11843184. DOI: 10.3892/etm.2025.12821.
Degron-Based bioPROTACs for Controlling Signaling in CAR T Cells.
Kim M, Bhargava H, Shavey G, Lim W, El-Samad H, Ng A ACS Synth Biol. 2024; 13(8):2313-2327.
PMID: 38991546 PMC: 11334183. DOI: 10.1021/acssynbio.4c00109.
He T, Wang Z, Li C, Zhao Y, Tong X, Liu J Pharmaceuticals (Basel). 2024; 17(6).
PMID: 38931471 PMC: 11206474. DOI: 10.3390/ph17060805.
Degron-based bioPROTACs for controlling signaling in CAR T cells.
Kim M, Bhargava H, Shavey G, Lim W, El-Samad H, Ng A bioRxiv. 2024; .
PMID: 38405763 PMC: 10888892. DOI: 10.1101/2024.02.16.580396.